Addus HomeCare/$ADUS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Addus HomeCare
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
- Ticker
- $ADUS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 28,321
- Headquarters
- Frisco, United States
- Website
- www.addus.com
Addus HomeCare Metrics
BasicAdvanced
$2.3B
21.30
$6.01
0.74
-
Price and volume
Market cap
$2.3B
Beta
0.74
52-week high
$130.40
52-week low
$87.95
Average daily volume
229K
Financial strength
Current ratio
1.64
Quick ratio
1.513
Long term debt to equity
0.046
Total debt to equity
0.057
Interest coverage (TTM)
19.42%
Profitability
EBITDA (TTM)
172.75
Gross margin (TTM)
32.32%
Net profit margin (TTM)
7.39%
Operating margin (TTM)
10.41%
Effective tax rate (TTM)
25.72%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
6.80%
Return on equity (TTM)
9.96%
Valuation
Price to earnings (TTM)
21.296
Price to revenue (TTM)
1.549
Price to book
2.01
Price to tangible book (TTM)
32.01
Price to free cash flow (TTM)
16.114
Free cash flow yield (TTM)
6.21%
Free cash flow per share (TTM)
7.94
Growth
Revenue change (TTM)
11.53%
Earnings per share change (TTM)
28.92%
3-year revenue growth (CAGR)
13.42%
10-year revenue growth (CAGR)
14.83%
3-year earnings per share growth (CAGR)
19.41%
10-year earnings per share growth (CAGR)
24.02%
What the Analysts think about Addus HomeCare
Analyst ratings (Buy, Hold, Sell) for Addus HomeCare stock.
Analyst projections of the future price of Addus HomeCare stock.
Bulls say / Bears say
Second-quarter revenue rose 8.0% year on year, while net income increased 25% and adjusted EBITDA rose 11.9%. That points to profitable growth, not just higher sales. (SEC)
The core personal care business delivered 6.8% organic revenue growth in the second quarter, and hospice grew 11.1%. State rate increases in Texas and Illinois also supported personal care revenue. (SEC)
The pending AccentCare personal care acquisition would add about $280 million in annualised revenue, roughly 19% to Addus’s revenue base, and expand its reach across 10 states. It could provide a sizable growth boost if completed and integrated well. (Investing.com, SEC)
Addus warns that federal Medicaid funding reductions could strain state budgets and lead to lower reimbursement or reduced coverage. Because personal care is its largest business, policy changes could weigh heavily on results. (SEC)
Caregiver shortages and wage pressure could constrain growth and margins. Addus says competition for workers remains significant and a shortage may stop it meeting demand, while future reimbursement increases are not assured to offset wage costs. (SEC)
Home health is still contracting: second-quarter organic revenue fell 2.8% year on year, and the segment generated only 4.6% of total revenue. This leaves an important part of the care offering contributing little to near-term growth. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
Addus HomeCare Financial Performance
Revenues and expenses
Addus HomeCare Earnings Performance
Company profitability
Upcoming events
No upcoming events
Addus HomeCare News
AllArticlesVideos
Funds containing Addus HomeCare
Fund name | Fund size | $ADUS weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.20% |
iShares Ageing Population£AGES | $953M | 0.20% |
iShares Ageing Population€AGED | $903M | 0.20% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.13% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.